Serplulimab Approved in the EU for First-Line Treatment of Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Serplulimab is the world's first anti-PD-1 monoclonal antibody (mAb) approved for first-line treatment of ES-SCLC Serplulimab is the first and only anti-PD-1 mAb approved in the European Union (EU) for the treatment of ES-SCLC Serplulimab has now...
Harbour BioMed Receives NMPA IND Clearance for HBM9378/SKB378 in the Treatment of Chronic Obstructive Pulmonary Disease
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, Feb. 5, 2025 /PRNewswire/ -- Harbour BioMed (HKEX: 02142, the "Company"), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody...
Thailand BOI Approves Investments Worth A Total of US$5 Billion, Including TikTok's Data Hosting Project; Green Lights Revised Incentives for the Bioeconomy
BANGKOK, Jan. 29, 2025 /PRNewswire/ -- The Thailand Board of Investment (BOI) today approved investment privileges for projects worth a combined 170.5 billion baht (ca. US$5 Billion) in value, including a digital infrastructure project by leading...
Korea Zinc Announces EGM Results, Affirming the Important Position the Company Holds in National Key Industry
SEOUL, South Korea, Jan. 24, 2025 /PRNewswire/ -- On January 23, Korea Zinc (KRX:010130) held an extraordinary general meeting (EGM) at Grand Hyatt Seoul to vote on eight agenda items proposed for amendments to the company's articles. Among these,...
Kelun-Biotech's Product Tagitanlimab Approved for Marketing in Second Indication in Combination with Cisplatin and Gemcitabine For the First-line Treatment of Patients with recurrent or metastatic NPC
CHENGDU, China, Jan. 23, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company received marketing authorization in China from National Medical Products Administration (NMPA) for the...
Purchasers of Quantstamp QSP Tokens May Be Eligible for Payment from the Quantstamp Fair Fund
COSTA MESA, Calif., Jan. 22, 2025 /PRNewswire/ -- The following statement is being issued by Simpluris, Inc., the SEC-appointed Fund Administrator. UNITED STATES OF AMERICA Before the SECURITIES AND EXCHANGE COMMISSION In the Matter of Quantstamp,...
Breaking Down Silos: IQAX eBL Interoperability Approved by IG P&I Clubs
HONG KONG, Jan. 22, 2025 /PRNewswire/ -- IQAX Limited's electronic bill of lading (eBL) solution has received approval from the International Group of P&I Clubs (IG P&I Clubs) for IQAX eBL interoperable addendum (version dated 6 December...
The Moskowitz Law Firm, PLLC Announces Preliminary Approval of a Proposed Class Action Settlement on Behalf of Purchasers of Astrals Non-Fungible Tokens and Galaxy Tokens
MIAMI, Jan. 18, 2025 /PRNewswire/ -- The Moskowitz Law Firm, PLLC announces the preliminary approval of a proposed class action settlement that would benefit purchasers and legal title holders of Astrals Non-Fungible Tokens or Galaxy Tokens: On...
Senaparib Approved by NMPA for 1L Maintenance Therapy in Ovarian Cancer
SHANGHAI, Jan. 17, 2025 /PRNewswire/ -- IMPACT Therapeutics ("IMPACT"), a biopharmaceutical company focusing on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality, is pleased to announce that Senaparib...
Thailand Approves Update of Long-Term Resident (LTR) Visa's Criteria and Conditions to Attract a Wider Range of Foreign Experts, Investors, and Executives
BANGKOK, Jan. 15, 2025 /PRNewswire/ -- The Thailand Board of Investment (BOI) announced today the approval by the Cabinet of updates and adjustments to the qualifications, criteria, and conditions for the Long-Term Resident (LTR) Visa program to...